The proceeds from the offering will be used to fund current operating expenses in order to continue the development of the Company's primary drug candidate, PRO 140, which is believed to be one of the leading monoclonal antibodies for the treatment of HIV.
http://www.hispanicbusiness.com/2013/10/24/cytodyn_inc_completes_14_5_million.htm
http://www.hispanicbusiness.com/2013/10/24/cytodyn_inc_completes_14_5_million.htm
No comments:
Post a Comment